NEW YORK, March 4, 2021 /PRNewswire/ -- AIkido Pharma Inc.
(NASDAQ: AIKI) ("AIkido" or the
"Company") today announced it will be featured as a presenting
company at the H.C. Wainwright Global Life Sciences Conference, a
virtual conference held March 9-10,
2021. The Company will showcase an updated Investor
Presentation and discuss some of its new technology. Darrell Dotson, Vice President and General
Counsel, of AIkido Pharma Inc. will present for the Company.
The presentation will be available on-demand starting at 7 a.m.
ET on Tuesday, March 9, 2021.
The "on demand" webcast of the event will be available for 90
days at
https://journey.ct.events/view/acd5b1e7-67aa-4aa4-83c4-3dd0eab43b60
If you are an institutional investor, and would like to attend
the Company's presentation, please click on the following link
https://hcwevents.com/globalconference/ to register for the
conference.
About H.C. Wainwright
H.C. Wainwright is a full–service investment bank dedicated to
providing corporate finance, strategic advisory and related
services to public and private companies across multiple sectors
and regions. H.C. Wainwright & Co. also provides research
and sales and trading services to institutional investors.
According to Sagient Research Systems, H.C. Wainwright's team is
ranked as the #1 Placement Agent in terms of aggregate CMPO
(confidentially marketed public offering), RD (registered direct
offering) and PIPE (private investment in public equity) executed
cumulatively since 1998.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology company with a diverse portfolio of small-molecule
anti-cancer therapeutics. The Company's platform consists of
patented technology from leading universities and researchers and
we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world
renowned educational institutions, including The University of
Texas at Austin and Wake
Forest University. Our diverse pipeline of therapeutics includes
therapies for pancreatic cancer, acute myeloid leukemia (AML) and
acute lymphoblastic leukemia (ALL). In addition, we are constantly
seeking to grow our pipeline to treat unmet medical needs in
oncology. The Company is also developing a broad-spectrum
antiviral platform that may potentially inhibit replication of
multiple viruses including Influenza virus, SARS-CoV (coronavirus),
MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor
Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-updates-announcement-of-webcast-link-for-the-hc-wainwright-global-life-sciences-conference-virtual-event-301240510.html
SOURCE AIkido Pharma Inc.